• ARCA Biopharma Inc., of Broomfield, Colo., has been notified by Nasdaq that the company has regained compliance with the minimum stockholders' equity requirement for continued listing.

• CardioDx Inc., of Fairfield, Conn., entered a strategic alliance with GE Healthcare to advance and co-develop genomic-based diagnostic technologies to improve the care and management of patients with cardiovascular disease. Under the terms, the GE Healthymagination Fund invested $5 million in CardioDx as part of a Series D round. Other financial terms were not disclosed.

• Genetic Immunity LLC, of McLean, Va., said that its paper on a stable liquid formulation it is developing to deliver a novel nanomedicine appeared in the International Journal of Pharmaceutics. The paper addresses how the company was able to overcome hurdles to formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir. The discoveries will support DermaVir as it enters into Phase II/III trials as a topically administered nanomedicine therapeutic vaccine.

• GenVec Inc., of Gaithersburg, Md., received notice from Nasdaq that its stock had fallen below the minimum $1 bid price for 30 consecutive business days. The firm has 180 days, or until Nov. 8, to regain compliance.

• Geron Corp., of Menlo Park, Calif., reported preclinical data showing that GRNCM1, its cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a guinea pig model of chronic heart damage designed to test that potential safety concern. Over the four-week monitoring period post-transplantation, researchers found no significant difference in the incidence of premature ventricular contractions or ventricular tachycardia between recipients of the cardiomyocytes or vehicle controls. Data were presented at the Heart Rhythm Society meeting in Denver. GRNCM1 is in development for heart failure.

• GTC Biotherapeutics Inc., of Framingham, Mass., said in its first quarter financial results that its cash will last to the end of the second quarter, after receiving a $7 million loan from partner LFB Biotechnologies, a subsidiary of LFB SA, of Les Ulis, France. The projected cash runway does not take into account any potential new partnering agreements or additional financing arrangements, the company said. The company's cash, as of April 3, was $4.9 million, a $1.1 million increase compared to $3.8 million in cash Jan. 3.

• Lorus Therapeutics Inc., of Toronto, said its board has approved a 1 to 30 stock consolidation. The timing of the consolidation will be determined later.

• MitoSciences Inc., of Eugene, Ore., was awarded $590,000 by the National Institutes of Health to support the development of companion diagnostic tests for antiviral drugs. The tests, developed in collaboration with the University of Oregon, are designed to allow clinicians to identify adverse effects from drugs used to treat HIV/AIDS, hepatitis and other infectious diseases, including effects that result in inhibition of mitochondrial function. The award was issued under the American Recovery and Reinvestment Act of 2009.

• NanoViricides Inc., of West Haven, Conn., signed an R&D agreement with Ken. S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy to evaluate the effectiveness of nanoviricide drug candidates against herpes simplex virus 1. Cell culture models, as well as in vivo studies will be used, and the testing is expected to help the company develop a drug against oral and genital herpes.

• Novavax Inc., of Rockville, Md., reported that positive results were published for its 2009 H1N1 influenza VLP vaccine. Ferrets were immunized with 3.75-, 7.5- or 15-mcg dose or a placebo then boosted with a second dose after three weeks. The vaccine was highly immunogenic, and all vaccinated animals, even in the lowest 3.75-mcg dose group, and developed hemagglutination inhibition antibody titers of 1:40 or higher, which is considered a protective level of immunity. Data were published in the May 12, 2010, issue of Vaccine.

• Omeros Corp., of Seattle, said that based on successful preclinical studies it has selected a candidate for its MASP-2 antibody program and has initiated the cGMP manufacturing development process in preparation for clinical trials. Preclinical studies showed that its fully human, monoclonal MASP-2 antibodies shut down the lectin pathway, which is involved in multiple inflammatory disorders. MASP-2 inhibition has also demonstrated efficacy across a wide range of preclinical disease models.

• RegeneRx Biopharmaceuticals Inc., of Rockville, Md., has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support clinical development of product candidate RGN-352, an injectable formulation of the peptide Thymosin beta 4 for patients who have suffered an acute myocardial infarction. The company plans to begin a Phase II trial with RGN-352 later this year.

• Viralytics Ltd., of Sydney, Australia, said that the FDA has confirmed that a specialist panel will meet June 22 for a pre-investigational new drug meeting, in which the agency will review a dossier on Viralytics' proposed Phase II melanoma trial. Viralytics plans to complete and file an IND application to conduct its international Phase II melanoma study in the U.S.